Hemera Biosciences is a Boston-based, clinical stage, gene therapy company targeting retinal diseases. HMR59, Hemera’s patented complement blocking AAV2 gene therapy platform, is developed to prevent progression of dry age-related macular degeneration (AMD) and its more advanced form, geographic atrophy (GA), with a single long acting injection. 

AMD is the leading cause of blindness and affects 8 million people in the U.S. and over 24 million people worldwide. No FDA approved treatment exists to halt the progression of dry AMD with scientific and clinical evidence implicating the complement system as the etiology. HMR59 through its protein product, soluble CD59 (sCD59), blocks 
the membrane attack complex (MAC), which is the terminal step of the complement cascade. HMR59 is designed to be dosed as a single intra ocular injection administered in an office setting whose benefit may last the life of the patient.

Additional ocular targets under pre clinical testing include wet AMD, diabetic eye disease, and uveitis. 


On December 30, 2016 the FDA granted “safe to proceed” status to Hemera's Investigational New Drug (IND) application for HMR59.  A phase 1 clinical trial in patients with advanced dry AMD is currently enrolling patients in the greater Boston area as of March 2017.  Details of Hemera's clinical trial, HMR1001, are available at: https://clinicaltrials.gov/show/NCT03144999

  


For more information about Hemera Biosciences or Hemera's ongoing Phase 1 Clinical Trial please email: info@hemerabiosciences.com



Website Builder